Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Activation of Nrf2 (unknown origin) expressed in CHO-ARE luc cells at 10 to 30 uM after 18 hrs by luciferase reporter gene assay | ChEMBL. | 24476568 | |
Activity (ADMET) | 0 | Cytotoxicity against human MCF7 cells | ChEMBL. | 17279798 |
Activity (ADMET) | 0 | Cytotoxicity against human Lu1 cells | ChEMBL. | 17279798 |
Activity (ADMET) | 0 | Cytotoxicity against human Col2 cells | ChEMBL. | 17279798 |
Activity (ADMET) | 0 | Cytotoxicity against human LNCaP cells | ChEMBL. | 17279798 |
Activity (ADMET) | 0 | Cytotoxicity against human TERT-RPE1 cells | ChEMBL. | 17279798 |
Activity (ADMET) | 0 | Cytotoxicity against human HUVEC cells | ChEMBL. | 17279798 |
Activity (binding) | = 1.7 % | Displacement of [3H]-CP55940 from human CB1 receptor transfected into HEK293 cells at 10 uM by microplate scintillation counting | ChEMBL. | 26035635 |
Activity (binding) | = 7.4 % | Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) transfected into HEK293 cells at 10 uM by microplate scintillation counting | ChEMBL. | 26035635 |
Activity (binding) | = 8.3 % | Displacement of [3H]-CP55940 from human CB2 receptor transfected into HEK293 cells at 10 uM by microplate scintillation counting | ChEMBL. | 26035635 |
Activity (binding) | = 31.6 % | Displacement of [3H]DPDPE from delta opioid receptor (unknown origin) transfected into HEK293 cells at 10 uM by microplate scintillation counting | ChEMBL. | 26035635 |
Activity (binding) | = 88 % | Agonist activity at human delta opioid receptor transfected into HEK293 cells assessed as effect on [35S]-GTPgammaS binding at 300 uM | ChEMBL. | 26035635 |
Ki (binding) | > 26 uM | Displacement of [3H]DPDPE from delta opioid receptor (unknown origin) transfected into HEK293 cells by microplate scintillation counting | ChEMBL. | 26035635 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
3 literature references were collected for this gene.